MSAM
MCRB icon

Moloney Securities Asset Management’s Seres Therapeutics MCRB Stock Holding History

Moloney Securities Asset Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,100
Closed -$105K – 343
2020
Q2 		$105K Buy
+1,100
New +$96.5K 0.03% 290

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Moloney Securities Asset Management's MCRB Position: Q3 2020 in Review

Moloney Securities Asset Management sold out of Seres Therapeutics (MCRB) in Q3 2020, closing a stake of 1,100 shares — an estimated $105K sold.

Moloney Securities Asset Management first reported a position in MCRB in Q2 2020 and held it in 1 quarter. The position peaked at $105K in Q2 2020. 113 funds tracked by Wall St. Rank hold MCRB as of Q3 2020.

  • Moloney Securities Asset Management reported no remaining Seres Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Moloney Securities Asset Management sold 1,100 Seres Therapeutics shares in Q3 2020, an estimated $105K.
  • Moloney Securities Asset Management first reported a position in Seres Therapeutics in Q2 2020 and held it in 1 quarter.
  • Moloney Securities Asset Management's Seres Therapeutics position peaked at $105K in Q2 2020.
  • 113 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2020.

Based on Moloney Securities Asset Management's 13F filing for Q3 2020, filed 20 Oct 2020.